Key result
The MEAD score, comprising non-contrast echocardiography parameters and absence of diabetes, predicted patent foramen ovale in ESUS patients with an AUC of 0.67.
Why the study?
The study was conducted to develop a screening score system based on non-contrast TTE to identify PFO in patients with ESUS.
Does the MEAD score measured with non-contrast TTE predict patent foramen ovale in patients with embolic stroke of undetermined source?
Observational (n=218)
No
Does the MEAD score measured with non-contrast TTE predict patent foramen ovale in patients with embolic stroke of undetermined source?
The MEAD score, derived from non-contrast TTE and clinical history, can serve as a screening tool to identify ESUS patients at high risk for PFO, potentially reducing unnecessary bubble tests.
Answers are grounded in this paper and cite their sources.
MEAD score shows modest PFO discrimination in ESUS; leaves open utility for selective bubble testing pending validation.
BACKGROUND: The aim of this study was to develop a screening score system of non-contrast transthoracic echocardiography (TTE) for patent foramen ovale (PFO) in patients with embolic stroke of undetermined source (ESUS). METHODS: We performed a retrospective analysis of 218 consecutive patients with a recent ESUS from 2015 to 2018, who received TTE and transcranial Doppler (TCD) as routine examinations. PFO was diagnosed by the bubble test of TCD. Significant differences of the non-contrast TTE findings and patient characteristics between PFO group and non-PFO group were selected into a score. RESULTS: PFO was diagnosed in 35.8% (78/218) of the patients. Compared with non-PFO group, a larger median aortic root diameter (ARd) (34 mm vs. 32 mm, p = 0.005), a lower median peak E wave velocity (Em) (61.5 cm/s vs. 68 cm/s, p = 0.005) and a lower incidence rate of mitral regurgitation (34.6% vs. 50.7%, p = 0.022) were seen in PFO group. ARd>33 mm and Em < 72 cm/s were the best thresholds to predict PFO in ROC analysis. A four-point score system (MEAD) including TTE criteria (including ARd>33 mm, Em < 72 cm/s and without mitral regurgitation) and no history of diabetes predicted PFO with an area under curve of 0.67 (95%CI 0.57-0.72, p < 0.001). MEAD score ≥ 3 was the best threshold to predict PFO with an accuracy of 0.64 (95% CI 0.57-0.7), a sensitivity of 0.65 (95% CI 0.53-0.75) and a specificity of 0.63 (95% CI 0.55-0.71). CONCLUSION: The MEAD score measured with non-contrast TTE can be used to select patients for bubble test of TCD to increase the diagnostic yield of PFO after ESUS.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted an observational in Embolic stroke of undetermined source (ESUS) (n=218). MEAD score vs. Transcranial Doppler bubble test was evaluated on Prediction of patent foramen ovale (PFO) (AUC 0.67, 95% CI 0.57-0.72, p=<0.001). The MEAD score, comprising non-contrast echocardiography parameters and absence of diabetes, predicted patent foramen ovale in ESUS patients with an AUC of 0.67.
Synapse has enriched 10 related papers. Consider them for comparative context: